- Home
- ALEC vs CBUS Comparison
ALEC vs CBUS Comparison
Compare ALEC & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | CBUS |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 142.7M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ALEC | CBUS |
|---|---|---|
| Price | $2.03 | $1.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.83 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.0M | 159.7K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,045,000.00 | $3,639,000.00 |
| Revenue This Year | $2.03 | $112.72 |
| Revenue Next Year | $29.87 | $83.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $1.09 |
| 52 Week High | $3.40 | $4.19 |
Technical Indicators
Market Signals| Indicator | ALEC | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 44.02 |
| Support Level | $1.93 | $1.56 |
| Resistance Level | $2.10 | $1.82 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 81.94 | 33.14 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.